Insperity reports Q1 2026 results tomorrow morning against a striking backdrop: the stock is up 33% in a month, short interest has climbed sharply since mid-March, and the CEO spent over $4 million buying shares near the lows. That is a lot of moving parts for a single earnings print to resolve.
The most compelling angle into tomorrow's call is the insider buying cluster from six weeks ago. Chairman and CEO Paul Sarvadi purchased roughly 200,000 shares across three days in mid-to-late March, committing approximately $4.6 million at prices in the low-to-mid $20s. The CFO added $204,500 on March 10, the General Counsel bought $24,000 on March 11, and an independent director topped up the same day. The breadth of participation — C-suite, legal, and the board — made this an unusual coordinated signal. The stock has since rallied to $35.25, already delivering roughly a 50% gain on those March purchases. Net insider buying over the 90 days through mid-March reached $5.3 million. The key question heading into tomorrow is whether the insiders were pricing in a fundamental recovery, or simply buying a beaten-down name that bounced with the broader tape.
Short sellers have not read the same playbook. SI has climbed from roughly 9% of the free float in mid-March to 11.3% now — a jump of more than two percentage points in six weeks, coinciding almost exactly with the price recovery. That tells a clear story: shorts rebuilt exposure as the stock recovered, treating the rally as an exit opportunity rather than a fundamental re-rating. The monthly rise in short interest of nearly 19% is the sharpest in the data window. Yet borrow conditions remain unremarkable — cost to borrow is just 0.51% annually, and availability in the lending pool remains comfortable. There is no squeeze dynamic at work. The ORTEX short score of 54.8 sits in roughly the middle of its recent range, and the short score factor rank of 13th percentile confirms shorts are more extended here than in most comparable names, but the borrow market itself is not strained.
Options positioning adds a modest layer of caution. The put/call ratio has drifted higher to 0.80, about 1.5 standard deviations above its 20-day average of 0.75 — not extreme, but the highest level of the past month. That directional skew towards puts suggests some hedging ahead of the print, though it is far from the defensive posturing that would signal widespread fear. The 52-week PCR range runs from 0.31 to 5.24, so the current reading is mild by historical standards.
The Street has been in sustained retreat on NSP for well over a year. The most recent analyst moves in the data — from Truist and JP Morgan in November 2025 — both lowered targets sharply, to $35 and $34 respectively, while maintaining cautious ratings. The consensus analyst data is now stale (as of February 2026), so the mean price target of $40.50 should be treated with caution given the series of downgrades and target cuts that preceded it. The bear case has centred on healthcare benefit cost overruns and weak workforce services employee growth; the bull case rests on the Workday partnership and the structural demand for outsourced HR among small and mid-size businesses. Q4 2025 results were poor — a net loss of $33 million for the quarter, with diluted loss per share of $0.88, versus a $0.22 loss in the prior year period. That print drove the stock's prior collapse from the $60s. The PE of 14.4x and EV/EBITDA of 5.3x reflect how far expectations have been reset.
Among peers, TriNet and BBSI each rose 3-4% on the day and 3-4% on the week, moving in line with the NSP recovery. ManpowerGroup gained 4% on the day but was slightly negative on the week, while ADP and Paychex trailed the group — the latter actually down 4% on the week. NSP's 11% weekly gain stands well above all of its correlated peers, implying idiosyncratic momentum rather than a sector-wide re-rating.
The earnings history adds context worth holding in mind. The February 2026 Q4 print triggered a one-day drop of roughly 18% and a five-day move of minus 32% — the kind of reaction that explains both why the stock reached the lows where insiders bought, and why options traders are carrying slightly elevated put protection today. Tomorrow's print is therefore less about whether Insperity's PEO model is growing, and more about whether healthcare benefit cost pressures have stabilised enough to restore credibility to any forward guidance.
See the live data behind this article on ORTEX.
Open NSP on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
